Breakout Ingredients Reshaping China's Food-Medicine Homology Market

Executive Summary

China's food-medicine homology ingredient market is undergoing a structural rebalancing. While bird's nest (CN¥ 7.54 billion), goji berry (CN¥ 3.61 billion), and ejiao (CN¥ 3.24 billion) continue to dominate absolute sales, the growth momentum has shifted decisively toward emerging ingredients. Astragalus surged +75.2% YoY, chicken's gizzard-membrane (ji nei jin) grew +55.0%, polygonatum expanded +45.6%, and angelica rose +42.5%. At the other extreme, ginseng plummeted -48.8% and cordyceps fell -30.6%, signaling that consumers are moving beyond traditional prestige toward condition-specific, accessible alternatives.

This ingredient shake-up extends across every major health segment. The "three highs" market grew +14.9% YoY to CN¥ 4.5 billion, liver care reached CN¥ 9.1 billion with +6.6% growth, and sleep aid ingredients diversified beyond dominant sour jujube seed with chrysanthemum surging +181.8%.

Download Full Report

For the complete ingredient ranking data, health segment breakdowns, and growth rate analysis across all 20 top ingredients, download the full whitepaper.

Download the Full 2025 Food-Medicine Homology Whitepaper →

The Top 20 Ingredients: Dominance vs. Momentum

Bird's nest commands the market at CN¥ 7.54 billion, more than double the second-ranked goji berry. The top three ingredients collectively account for over CN¥ 14.39 billion, representing a dominant premium tier anchored by established consumer trust and gift economy demand.

However, the growth story lies in the mid-tier and emerging ingredients. Astragalus, despite ranking ninth by absolute sales at CN¥ 1.71 billion, posted the fastest growth in the top 20 at +75.2% YoY. Chicken's gizzard-membrane (ji nei jin), traditionally used for digestive health, achieved CN¥ 793 million with +55.0% growth. Polygonatum reached CN¥ 373 million with +45.6% growth.

Bird's nest dominates at CN¥ 7.54 billion, but astragalus and ji nei jin show strongest growth

Bird's nest dominates at CN¥ 7.54 billion, but astragalus and ji nei jin show strongest growth

*Source: Moojing Market Intelligence*

Qi and Blood Nourishment: The Largest Segment Rebalances

The qi and blood nourishment segment -- the largest in the food-medicine homology category -- contracted to CN¥ 25.85 billion, down -4.3% YoY. This headline decline masks significant internal divergence. Polygonatum led segment growth at +45.6%, followed by astragalus (+19.9%) and ejiao (+16.2%). These three ingredients drive a "premiumization from below" dynamic, where consumers upgrade to ingredient-specific formulations without paying the ultra-premium prices of cordyceps (-30.6%) or ginseng (-48.8%).

The contraction concentrates in high-price, low-frequency traditional tonic products. Affordable daily wellness products within the qi and blood category continue to grow, mirroring the broader market's shift from premium gifting toward everyday health maintenance.

For portfolio strategy, the data supports a barbell approach: maintaining presence in stable, high-volume ingredients (bird's nest, goji berry, ejiao) while aggressively scaling high-growth emerging ingredients that represent the segment's future growth engine.

Three Highs: The Fastest-Growing Health Segment

The "three highs" segment -- addressing hypertension, hyperglycemia, and hyperlipidemia -- delivered the market's strongest growth at +14.9% YoY, reaching CN¥ 4.55 billion. Growth accelerated from +9.6% in 2023, suggesting the segment has entered a rapid adoption phase.

Within this segment, ingredient growth shows extraordinary dispersion. Honeysuckle surged +131.2%, more than doubling its sales. Cinnamon grew +98.9%, reflecting rising interest in metabolic health ingredients. Hawthorn (+63.1%), eucommia bark (+56.5%), and gastrodia (+53.2%) also demonstrated exceptional growth.

The high blood sugar sub-segment commands the largest share at over CN¥ 1.5 billion with +25.7% YoY growth. With China's diabetic and pre-diabetic population exceeding 140 million, this sub-segment represents one of the highest-conviction investment opportunities in the food-medicine homology space.

Liver Care: TCM Alternatives Challenge Western Supplements

The liver care segment exceeded CN¥ 9.1 billion at +6.6% YoY, making it the second-largest health segment. The standout trend is a consumer preference shift from Western-origin ingredients toward TCM alternatives.

White peony root achieved +210.8% YoY growth -- the most dramatic ingredient trajectory in the entire food-medicine homology market. Reishi mushroom grew +47.7% and goji berry rose +16.8% within the liver care context. Meanwhile, milk thistle -- the segment leader at CN¥ 2.76 billion -- declined -13.7%, and kudzu root fell -50.8%.

This divergence creates opportunities for brands that develop liver care formulations rooted in TCM principles, particularly as consumers seek to reduce dependence on imported supplements.

Sleep Aid: Ingredient Diversification Beyond Sour Jujube Seed

The sleep aid segment reached CN¥ 624 million, with sour jujube seed commanding 81% of ingredient sales at CN¥ 505 million. However, sour jujube seed grew only +0.9%, essentially flat, while emerging ingredients exploded.

Chrysanthemum surged +181.8%, schisandra grew +178.5%, longan meat rose +113.1%, and reishi mushroom expanded +101.7%. These four ingredients, traditionally associated with calming and sedative properties in TCM, are appearing in innovative formats such as functional teas and sleep sprays.

Given that 36% of consumers identify sleep problems as a primary health concern, the gap between current market size (CN¥ 624 million) and total addressable demand suggests significant headroom for growth. Multi-ingredient formulations combining established sour jujube seed with high-growth emerging ingredients may capture the next wave of segment expansion.

Strategic Implications for Brands and Investors

The ingredient-level data points to three strategic priorities. First, portfolio diversification away from declining premium ingredients toward high-growth alternatives with strong health-condition alignment. Second, multi-ingredient formulation strategies, particularly in the three highs and sleep aid segments where consumers seek synergistic combinations. Third, ingredient education investment, given that 62% of consumer attention focuses on ingredient information above all other purchase factors.

Brands that identify and scale high-growth ingredients early -- before they mature into stable mid-growth categories -- stand to capture disproportionate market share in this rapidly evolving CN¥ 56.78 billion market.

About the Data

This analysis draws on Moojing Market Intelligence's proprietary transaction data across Taobao, Tmall, JD.com, and Douyin, covering 400,000+ brands and 58-65% of China's online retail GMV. Ingredient classification references the National Health Commission's official food-medicine homology ingredient lists. All growth rates are calculated on a year-on-year basis using consistent category definitions across the 2022-2024 period.

For methodology details, data sourcing, and complete market analysis, download the full report.

Download the Full 2025 Food-Medicine Homology Whitepaper →